Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study-Reference-Cited by-同舟云学术

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study

Published:2017-08 Issue:8 Volume:28 Page:1996-2001
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cabel L.,Riva F.,Servois V.,Livartowski A.,Daniel C.,Rampanou A.,Lantz O.,Romano E.,Milder M.,Buecher B.,Piperno-Neumann S.,Bernard V.,Baulande S.,Bieche I.,Pierga J.Y.,Proudhon C.,Bidard F.-C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/8/1996/19388797/mdx212.pdf

Reference21 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N. Engl. J. Med,2015

4. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N. Engl. J. Med,2015

5. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N. Engl. J. Med,2015

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report;Cureus;2024-09-12

2. Liquid biopsy: paving a new avenue for cancer research;Cell Adhesion & Migration;2024-09

3. Optimizing ctDNA: An Updated Review of a Promising Clinical Tool for the Management of Uveal Melanoma;Cancers;2024-09-01

4. Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives;Biomedicines;2024-08-05

5. The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden;The Journal of Molecular Diagnostics;2024-08